Article thumbnail

A Computational Approach to Finding Novel Targets for Existing Drugs

By Yvonne Y. Li, Jianghong An and Steven J. M. Jones


Repositioning existing drugs for new therapeutic uses is an efficient approach to drug discovery. We have developed a computational drug repositioning pipeline to perform large-scale molecular docking of small molecule drugs against protein drug targets, in order to map the drug-target interaction space and find novel interactions. Our method emphasizes removing false positive interaction predictions using criteria from known interaction docking, consensus scoring, and specificity. In all, our database contains 252 human protein drug targets that we classify as reliable-for-docking as well as 4621 approved and experimental small molecule drugs from DrugBank. These were cross-docked, then filtered through stringent scoring criteria to select top drug-target interactions. In particular, we used MAPK14 and the kinase inhibitor BIM-8 as examples where our stringent thresholds enriched the predicted drug-target interactions with known interactions up to 20 times compared to standard score thresholds. We validated nilotinib as a potent MAPK14 inhibitor in vitro (IC50 40 nM), suggesting a potential use for this drug in treating inflammatory diseases. The published literature indicated experimental evidence for 31 of the top predicted interactions, highlighting the promising nature of our approach. Novel interactions discovered may lead to the drug being repositioned as a therapeutic treatment for its off-target's associated disease, added insight into the drug's mechanism of action, and added insight into the drug's side effects

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A quantitative analysis of kinase inhibitor selectivity.
  2. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors.
  3. (2007). A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
  4. (2010). Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of
  5. (2010). Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
  6. (2003). Balloonoccluded retrograde transvenous obliteration for gastric variceal bleeding: Its feasibility compared with transjugular intrahepatic portosystemic shunt.
  7. (2006). Benchmarking sets for molecular docking.
  8. (2005). Cellular targets of gefitinib.
  9. (2005). Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl.
  10. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
  11. (2010). Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol.
  12. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
  13. (2000). Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein.
  14. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks.
  15. (2006). Diabetes: Assessing the pipeline.
  16. (1995). Differential activation of peroxisome proliferator-activated receptors by eicosanoids.
  17. (2009). Docking and chemoinformatic screens for new ligands and targets.
  18. (2005). Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection.
  19. (2004). Drospirenone, a progestogen with antimineralocorticoid properties: A short review.
  20. (2009). Drug discovery using chemical systems biology: Repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis.
  21. (2007). Drug output slows in
  22. (2004). Drug repositioning: Identifying and developing new uses for existing drugs.
  23. (2008). Drug target identification using side-effect similarity.
  24. (2006). DrugBank: A comprehensive resource for in silico drug discovery and exploration.
  25. (2000). Effect of receptor-selective retinoids on growth and differentiation pathways in mouse melanoma cells.
  26. (2009). Effects of protein conformation in docking: Improved pose prediction through protein pocket adaptation.
  27. (2009). Emerging drugs for psoriasis.
  28. (2010). Extended kinase profile and properties of the protein kinase inhibitor nilotinib.
  29. FanjulAN,DeliaD,PierottiMA,RideoutD,YuJQ,etal.(1996)4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors.
  30. (2002). High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate.
  31. (2001). High-throughput docking for lead generation.
  32. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge Nature Reviews Drug Discovery. 10.1038/nrd3078. Available: via the Internet.
  33. (1994). ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation.
  34. (2008). Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
  35. (2004). Imatinib as a paradigm of targeted therapies.
  36. (2007). Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
  37. (2006). In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
  38. (2008). Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
  39. (2008). Methylenetetrahydrofolate reductase (MTHFR): A novel target for cancer therapy.
  40. (2002). Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women.
  41. (1996). Mutation of the pleckstrin homology domain of bruton’s tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity.
  42. (2003). p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases.
  43. (2005). Pocketome via comprehensive identification and classification of ligand binding envelopes.
  44. (2004). Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain.
  45. (2009). Predicting new molecular targets for known drugs.
  46. (2008). Protein-ligand docking against non-native protein conformers.
  47. (2000). PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
  48. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
  49. (2009). Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
  50. (2009). Selectivity and therapeutic inhibition of kinases: To be or not to be?
  51. (2002). SLIPPER-2001 – software for predicting molecular properties on the basis of physicochemical descriptors and structural similarity.
  52. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
  53. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors.
  54. (2000). Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
  55. (2004). Structure of human erythrocyte NADH-cytochrome b5 reductase.
  56. (2004). The many roles of computation in drug discovery.
  57. (1996). The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential.
  58. (2003). The SWISS-PROT protein knowledgebase and its supplement TrEMBL
  59. (2010). The universal protein resource (UniProt) in 2010.
  60. (2001). Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase.
  61. (2008). Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. part 2: Identification of active compounds.
  62. (2003). Vitamin D receptor as a drug discovery target.